Our Mission: Improving and Extending the Lives of Patients with Cancer
  
 
 About Celator®   |   Products   |   CombiPlex®   |   Publications   |   News & Events   |   Contact   |   Investors
  CPX-351       CPX-1
 

Clinical Products

Celator has multiple products in clinical development and preclinical programs:

  • CPX-351 (Cytarabine:Daunorubicin) – Currently in Phase 3 clinical trial in patients with untreated high-risk (secondary) acute myeloid leukemia. 
    Learn more about CPX-351.

  • CPX-1 (Irinotecan HCI:Floxuridine) – Completed a Phase 2 clinical trial in patients with colorectal cancer. 
    Learn more about CPX-1.

  • CPX-571 (Irinotecan HCl:Cisplatin) – A preclinical stage product for solid tumors. 
    Learn more about CPX-571.
  • CPX-8 – Nanoparticle delivery system developed in conjunction with Princeton University, currently in early stage research.
    Learn more about CPX-8.

  • Other Preclinical Programs – Researchers at Celator have identified multiple preclinical programs to treat a range of cancers.

       

 

 

 


Celator’s drug pipeline includes therapies targeting acute myeloid leukemia, colorectal cancer, and small cell lung cancer.

 

 

 

 

 

 

 

 

 

  
© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.